摘要
目的:对磺脲类药物联合二甲双胍治疗2型糖尿病患者的经济学进行评价,为临床合理用药、降低医疗费用提供参考。方法:系统检索Pub Med、Embase、中国知网和万方医学网有关磺脲类药物的经济学评价的文章。结果:检索到文献13篇,分别为磺脲类药物联合二甲双胍与二肽基肽酶(dipeptidyl peptidase-4,DPP-4)抑制剂、胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂、α-糖苷酶抑制剂、噻唑烷二酮类、格列奈类、胰岛素以及不同磺脲类药物在联合二甲双胍基础上的经济学比较研究。结论:在联用二甲双胍基础上,与DPP-4抑制剂类、GLP-1受体激动剂、α-糖苷酶抑制剂、噻唑烷二酮类、格列奈类、胰岛素等相比,磺脲类表现出较好的成本-效益,其中中格列本脲、格列美脲的经济性较好。
Objective:To evaluate the pharmacoeconomics of sulfonylureas add-on to metformin in patients with type2diabetes.To provide reference for rational use of drugs in clinic and reducing the cost of health care.Methods:Studies about pharmacoeconomic evaluation of sulfonylureas were searched form PubMed,Embase,CNKI and Wanfang Med Online.Results:13studies about pharmacoeconomic evaluation were selected,which involved the comparison between sulfonylureas/metformin to other agents/metformin,including DPP-4inhibitor,GLP-1agonist,α-glucosidase,inhibitor,thiazolidinediones,meglitinide,insulin and other sulfonylureas.Conclusion:As add-on to metformin,treatment with other agents,including DPP-4inhibitor,GLP-1agonist,α-glucosidase,inhibitor,thiazolidinediones,meglitinide and insulin,had unfavourable cost-effectiveness estimates compared with sulfonylureas.Glibenclamide and glimepiride were associated with the most favourable cost-effectiveness among sulfonylureas.
作者
王静
杨婉花
WANG Jing;YANG Wan-hua(Department of Pharmacy, Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China)
出处
《药品评价》
CAS
2017年第3期45-49,共5页
Drug Evaluation
